{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:03Z","timestamp":1790832423657,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["#11\/2019"],"award-info":[{"award-number":["#11\/2019"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["#07\/2020"],"award-info":[{"award-number":["#07\/2020"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["#19\/2019"],"award-info":[{"award-number":["#19\/2019"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PEDEMO20G0"],"award-info":[{"award-number":["PEDEMO20G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Italian Ministry of Health","award":["GR-2018-12367126"],"award-info":[{"award-number":["GR-2018-12367126"]}]},{"DOI":"10.13039\/501100003500","name":"University of Padova","doi-asserted-by":"crossref","award":["BORG_BIRD2121_01 - BIRD 2021"],"award-info":[{"award-number":["BORG_BIRD2121_01 - BIRD 2021"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The advent of Trikafta (Kaftrio in Europe) (a triple-combination therapy based on two correctors\u2014elexacaftor\/tezacaftor\u2014and the potentiator ivacaftor) has represented a revolution for the treatment of patients with cystic fibrosis (CF) carrying the most common misfolding mutation, F508del-CFTR. This therapy has proved to be of great efficacy in people homozygous for F508del-CFTR and is also useful in individuals with a single F508del allele. Nevertheless, the efficacy of this therapy needs to be improved, especially in light of the extent of its use in patients with rare class II CFTR mutations. Using CFBE41o- cells expressing F508del-CFTR, we provide mechanistic evidence that targeting the E1 ubiquitin-activating enzyme (UBA1) by TAK-243, a small molecule in clinical trials for other diseases, boosts the rescue of F508del-CFTR induced by CFTR correctors. Moreover, TAK-243 significantly increases the F508del-CFTR short-circuit current induced by elexacaftor\/tezacaftor\/ivacaftor in differentiated human primary airway epithelial cells, a gold standard for the pre-clinical evaluation of patients\u2019 responsiveness to pharmacological treatments. This new combinatory approach also leads to an improvement in CFTR conductance on cells expressing other rare CF-causing mutations, including N1303K, for which Trikafta is not approved. These findings show that Trikafta therapy can be improved by the addition of a drug targeting the misfolding detection machinery at the beginning of the ubiquitination cascade and may pave the way for an extension of Trikafta to low\/non-responding rare misfolded CFTR mutants.<\/jats:p>","DOI":"10.1007\/s00018-022-04215-3","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T04:43:35Z","timestamp":1647405815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants"],"prefix":"10.1007","volume":"79","author":[{"given":"Christian","family":"Borgo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Capurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tomati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Sondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Cresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-6048","authenticated-orcid":false,"given":"Mauro","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"4215_CR1","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC (2021) Cystic fibrosis. The Lancet 397:2195\u20132211. https:\/\/doi.org\/10.1016\/S0140-6736(20)32542-3","journal-title":"The Lancet"},{"key":"4215_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.E14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit G, Avramescu RG, Chiang AN et al (2016) From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27:424\u2013433. https:\/\/doi.org\/10.1091\/mbc.E14-04-0935","journal-title":"Mol Biol Cell"},{"key":"4215_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","volume":"18","author":"SD Sagel","year":"2020","unstructured":"Sagel SD, Khan U, Heltshe SL et al (2020) Clinical effectiveness of lumacaftor\/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A clinical trial. Annals ATS 18:75\u201383. https:\/\/doi.org\/10.1513\/AnnalsATS.202002-144OC","journal-title":"Annals ATS"},{"key":"4215_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381:1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"key":"4215_CR5","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/ijms22105262","volume":"22","author":"V Capurro","year":"2021","unstructured":"Capurro V, Tomati V, Sondo E et al (2021) Partial rescue of F508del-CFTR stability and trafficking defects by double corrector treatment. Int J Mol Sci 22:5262. https:\/\/doi.org\/10.3390\/ijms22105262","journal-title":"Int J Mol Sci"},{"key":"4215_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00671-2021","author":"F Becq","year":"2021","unstructured":"Becq F, Mirval S, Carrez T et al (2021) The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00671-2021","journal-title":"Eur Respir J"},{"key":"4215_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04168-y","author":"MC Bierlaagh","year":"2021","unstructured":"Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK (2021) A new era for people with cystic fibrosis. Eur J Pediatr. https:\/\/doi.org\/10.1007\/s00431-021-04168-y","journal-title":"Eur J Pediatr"},{"key":"4215_CR8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139983","author":"G Veit","year":"2020","unstructured":"Veit G, Roldan A, Hancock MA et al (2020) Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.139983","journal-title":"JCI Insight"},{"key":"4215_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02774-2020","author":"O Laselva","year":"2020","unstructured":"Laselva O, Bartlett C, Gunawardena TNA et al (2020) Rescue of multiple class II CFTR mutations by elexacaftor+ tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.02774-2020","journal-title":"Eur Respir J"},{"key":"4215_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/jpm11070643","volume":"11","author":"G Veit","year":"2021","unstructured":"Veit G, Velkov T, Xu H et al (2021) A precision medicine approach to optimize modulator therapy for rare CFTR folding mutants. J Pers Med 11:643. https:\/\/doi.org\/10.3390\/jpm11070643","journal-title":"J Pers Med"},{"key":"4215_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","volume":"83","author":"CL Ward","year":"1995","unstructured":"Ward CL, Omura S, Kopito RR (1995) Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121\u2013127. https:\/\/doi.org\/10.1016\/0092-8674(95)90240-6","journal-title":"Cell"},{"key":"4215_CR12","doi-asserted-by":"publisher","first-page":"e68001","DOI":"10.1371\/journal.pone.0068001","volume":"8","author":"J Cheng","year":"2013","unstructured":"Cheng J, Guggino W (2013) Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6. PLoS ONE 8:e68001. https:\/\/doi.org\/10.1371\/journal.pone.0068001","journal-title":"PLoS ONE"},{"key":"4215_CR13","doi-asserted-by":"publisher","first-page":"31177","DOI":"10.1074\/jbc.M113.470500","volume":"288","author":"E El Khouri","year":"2013","unstructured":"El Khouri E, Le Pavec G, Toledano MB, Delaunay-Moisan A (2013) RNF185 is a novel E3 ligase of endoplasmic reticulum-associated degradation (ERAD) that targets cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem 288:31177\u201331191. https:\/\/doi.org\/10.1074\/jbc.M113.470500","journal-title":"J Biol Chem"},{"key":"4215_CR14","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1091\/mbc.e07-06-0601","volume":"19","author":"D Morito","year":"2008","unstructured":"Morito D, Hirao K, Oda Y et al (2008) Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTRDeltaF508. Mol Biol Cell 19:1328\u20131336. https:\/\/doi.org\/10.1091\/mbc.e07-06-0601","journal-title":"Mol Biol Cell"},{"key":"4215_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/35050509","volume":"3","author":"GC Meacham","year":"2001","unstructured":"Meacham GC, Patterson C, Zhang W et al (2001) The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 3:100\u2013105. https:\/\/doi.org\/10.1038\/35050509","journal-title":"Nat Cell Biol"},{"key":"4215_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1091\/mbc.E12-09-0678","volume":"24","author":"A Ahner","year":"2013","unstructured":"Ahner A, Gong X, Schmidt BZ et al (2013) Small heat shock proteins target mutant cystic fibrosis transmembrane conductance regulator for degradation via a small ubiquitin-like modifier-dependent pathway. Mol Biol Cell 24:74\u201384. https:\/\/doi.org\/10.1091\/mbc.E12-09-0678","journal-title":"Mol Biol Cell"},{"key":"4215_CR17","doi-asserted-by":"publisher","first-page":"12138","DOI":"10.1038\/srep12138","volume":"5","author":"V Tomati","year":"2015","unstructured":"Tomati V, Sondo E, Armirotti A et al (2015) Genetic inhibition of the ubiquitin ligase Rnf5 attenuates phenotypes associated to F508del cystic fibrosis mutation. Sci Rep 5:12138. https:\/\/doi.org\/10.1038\/srep12138","journal-title":"Sci Rep"},{"key":"4215_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.devcel.2018.02.001","volume":"44","author":"T Okiyoneda","year":"2018","unstructured":"Okiyoneda T, Veit G, Sakai R et al (2018) Chaperone-independent peripheral quality control of CFTR by RFFL E3 ligase. Dev Cell 44:694-708.e7. https:\/\/doi.org\/10.1016\/j.devcel.2018.02.001","journal-title":"Dev Cell"},{"key":"4215_CR19","unstructured":"(2019) Degradation of CFTR-F508del by the ubiquitin E2 conjugating enzyme UBE 2L6 and the E3 ligase RNF19B. https:\/\/www.researchsquare.com. Accessed 12 Apr 2021"},{"key":"4215_CR20","doi-asserted-by":"publisher","first-page":"e0163615","DOI":"10.1371\/journal.pone.0163615","volume":"11","author":"WJ Chung","year":"2016","unstructured":"Chung WJ, Goeckeler-Fried JL, Havasi V et al (2016) Increasing the endoplasmic reticulum pool of the F508del allele of the cystic fibrosis transmembrane conductance regulator leads to greater folding correction by small molecule therapeutics. PLoS ONE 11:e0163615. https:\/\/doi.org\/10.1371\/journal.pone.0163615","journal-title":"PLoS ONE"},{"key":"4215_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bcp.2011.05.012","volume":"82","author":"V Kapuria","year":"2011","unstructured":"Kapuria V, Peterson LF, Showalter HDH et al (2011) Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity. Biochem Pharmacol 82:341\u2013349. https:\/\/doi.org\/10.1016\/j.bcp.2011.05.012","journal-title":"Biochem Pharmacol"},{"key":"4215_CR22","doi-asserted-by":"publisher","first-page":"128243","DOI":"10.1016\/j.bmcl.2021.128243","volume":"48","author":"JL Goeckeler-Fried","year":"2021","unstructured":"Goeckeler-Fried JL, Aldrin Denny R, Joshi D et al (2021) Improved correction of F508del-CFTR biogenesis with a folding facilitator and an inhibitor of protein ubiquitination. Bioorg Med Chem Lett 48:128243. https:\/\/doi.org\/10.1016\/j.bmcl.2021.128243","journal-title":"Bioorg Med Chem Lett"},{"key":"4215_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","volume":"24","author":"ML Hyer","year":"2018","unstructured":"Hyer ML, Milhollen MA, Ciavarri J et al (2018) A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med 24:186\u2013193. https:\/\/doi.org\/10.1038\/nm.4474","journal-title":"Nat Med"},{"key":"4215_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092250","author":"F Wang","year":"2019","unstructured":"Wang F, Zhao B (2019) UBA6 and its bispecific pathways for ubiquitin and FAT10. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20092250","journal-title":"Int J Mol Sci"},{"key":"4215_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.010","author":"C D\u2019Amore","year":"2021","unstructured":"D\u2019Amore C, Borgo C, Salvi M (2021) A mutational approach to dissect the functional role of the putative CFTR \u201cPTM-CODE.\u201d J Cyst Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.010","journal-title":"J Cyst Fibros"},{"key":"4215_CR26","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1113\/jphysiol.2012.240838","volume":"590","author":"P Scudieri","year":"2012","unstructured":"Scudieri P, Caci E, Bruno S et al (2012) Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol 590:6141\u20136155. https:\/\/doi.org\/10.1113\/jphysiol.2012.240838","journal-title":"J Physiol"},{"key":"4215_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","volume":"19","author":"H Mou","year":"2016","unstructured":"Mou H, Vinarsky V, Tata PR et al (2016) Dual SMAD signaling inhibition enables long-term expansion of diverse epithelial basal cells. Cell Stem Cell 19:217\u2013231. https:\/\/doi.org\/10.1016\/j.stem.2016.05.012","journal-title":"Cell Stem Cell"},{"key":"4215_CR28","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1074\/jbc.M009172200","volume":"276","author":"M Sharma","year":"2001","unstructured":"Sharma M, Benharouga M, Hu W, Lukacs GL (2001) Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 276:8942\u20138950. https:\/\/doi.org\/10.1074\/jbc.M009172200","journal-title":"J Biol Chem"},{"key":"4215_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-1-61779-117-8_2","volume":"741","author":"N Pedemonte","year":"2011","unstructured":"Pedemonte N, Zegarra-Moran O, Galietta LJV (2011) High-throughput screening of libraries of compounds to identify CFTR modulators. Methods Mol Biol 741:13\u201321. https:\/\/doi.org\/10.1007\/978-1-61779-117-8_2","journal-title":"Methods Mol Biol"},{"key":"4215_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732\u2013736. https:\/\/doi.org\/10.1038\/nature07884","journal-title":"Nature"},{"key":"4215_CR31","doi-asserted-by":"publisher","first-page":"25489","DOI":"10.1074\/jbc.M116.754283","volume":"291","author":"S Ramachandran","year":"2016","unstructured":"Ramachandran S, Osterhaus SR, Parekh KR et al (2016) SYVN1, NEDD8, and FBXO2 proteins regulate \u0394F508 cystic fibrosis transmembrane conductance regulator (CFTR) ubiquitin-mediated proteasomal degradation. J Biol Chem 291:25489\u201325504. https:\/\/doi.org\/10.1074\/jbc.M116.754283","journal-title":"J Biol Chem"},{"key":"4215_CR32","doi-asserted-by":"publisher","first-page":"eaay9669","DOI":"10.1126\/sciadv.aay9669","volume":"6","author":"N Pedemonte","year":"2020","unstructured":"Pedemonte N, Bertozzi F, Caci E et al (2020) Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel. Sci Adv 6:eaay9669. https:\/\/doi.org\/10.1126\/sciadv.aay9669","journal-title":"Sci Adv"},{"key":"4215_CR33","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/cbdd.12571","volume":"86","author":"X Wang","year":"2015","unstructured":"Wang X, D\u2019Arcy P, Caulfield TR et al (2015) Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des 86:1036\u20131048. https:\/\/doi.org\/10.1111\/cbdd.12571","journal-title":"Chem Biol Drug Des"},{"key":"4215_CR34","doi-asserted-by":"publisher","first-page":"246ra97","DOI":"10.1126\/scitranslmed.3008889","volume":"6","author":"G Veit","year":"2014","unstructured":"Veit G, Avramescu RG, Perdomo D et al (2014) Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression. Sci Transl Med 6:246ra97. https:\/\/doi.org\/10.1126\/scitranslmed.3008889","journal-title":"Sci Transl Med"},{"key":"4215_CR35","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1074\/jbc.M116.764720","volume":"292","author":"PM Haggie","year":"2017","unstructured":"Haggie PM, Phuan P-W, Tan J-A et al (2017) Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane regulator (CFTR) translation product. J Biol Chem 292:771\u2013785. https:\/\/doi.org\/10.1074\/jbc.M116.764720","journal-title":"J Biol Chem"},{"key":"4215_CR36","doi-asserted-by":"publisher","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","volume":"301","author":"E Sondo","year":"2011","unstructured":"Sondo E, Tomati V, Caci E et al (2011) Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 301:C872\u2013C885. https:\/\/doi.org\/10.1152\/ajpcell.00507.2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"4215_CR37","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1074\/jbc.M117.816595","volume":"293","author":"V Tomati","year":"2018","unstructured":"Tomati V, Pesce E, Caci E et al (2018) High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel. J Biol Chem 293:1203\u20131217. https:\/\/doi.org\/10.1074\/jbc.M117.816595","journal-title":"J Biol Chem"},{"key":"4215_CR38","doi-asserted-by":"publisher","first-page":"18843","DOI":"10.1073\/pnas.1105787108","volume":"108","author":"F Van Goor","year":"2011","unstructured":"Van Goor F, Hadida S, Grootenhuis PDJ et al (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108:18843\u201318848. https:\/\/doi.org\/10.1073\/pnas.1105787108","journal-title":"Proc Natl Acad Sci USA"},{"key":"4215_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.biocel.2017.05.002","volume":"88","author":"A Bergougnoux","year":"2017","unstructured":"Bergougnoux A, Petit A, Knabe L et al (2017) The HDAC inhibitor SAHA does not rescue CFTR membrane expression in cystic fibrosis. Int J Biochem Cell Biol 88:124\u2013132. https:\/\/doi.org\/10.1016\/j.biocel.2017.05.002","journal-title":"Int J Biochem Cell Biol"},{"key":"4215_CR40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","volume":"4","author":"K De Boeck","year":"2016","unstructured":"De Boeck K, Amaral MD (2016) Progress in therapies for cystic fibrosis. Lancet Respir Med 4:662\u2013674. https:\/\/doi.org\/10.1016\/S2213-2600(16)00023-0","journal-title":"Lancet Respir Med"},{"key":"4215_CR41","doi-asserted-by":"publisher","unstructured":"van Willigen M, Vonk AM, Yeoh HY, et al (2019) Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants. Life Sci Alliance 2:e201800172. https:\/\/doi.org\/10.26508\/lsa.201800172","DOI":"10.26508\/lsa.201800172"},{"key":"4215_CR42","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M (2019) CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 10:1662. https:\/\/doi.org\/10.3389\/fphar.2019.01662","journal-title":"Front Pharmacol"},{"key":"4215_CR43","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.4161\/cc.9.21.13741","volume":"9","author":"EM Rubenstein","year":"2010","unstructured":"Rubenstein EM, Hochstrasser M (2010) Redundancy and variation in the ubiquitin-mediated proteolytic targeting of a transcription factor. Cell Cycle 9:4282\u20134285. https:\/\/doi.org\/10.4161\/cc.9.21.13741","journal-title":"Cell Cycle"},{"key":"4215_CR44","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1083\/jcb.143.7.1883","volume":"143","author":"JA Johnston","year":"1998","unstructured":"Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143:1883\u20131898. https:\/\/doi.org\/10.1083\/jcb.143.7.1883","journal-title":"J Cell Biol"},{"key":"4215_CR45","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ymthe.2020.02.001","volume":"28","author":"C De Santi","year":"2020","unstructured":"De Santi C, Fern\u00e1ndez Fern\u00e1ndez E, Gaul R et al (2020) Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells. Mol Ther 28:1190\u20131199. https:\/\/doi.org\/10.1016\/j.ymthe.2020.02.001","journal-title":"Mol Ther"},{"key":"4215_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/2472555217729790","volume":"23","author":"KA Giuliano","year":"2018","unstructured":"Giuliano KA, Wachi S, Drew L et al (2018) Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors. SLAS Discov 23:111\u2013121. https:\/\/doi.org\/10.1177\/2472555217729790","journal-title":"SLAS Discov"},{"key":"4215_CR47","doi-asserted-by":"publisher","unstructured":"Molinski SV, Ahmadi S, Ip W, et al (2017) Orkambi\u00ae and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. EMBO Mol Med 9:1224\u20131243. https:\/\/doi.org\/10.15252\/emmm.201607137","DOI":"10.15252\/emmm.201607137"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04215-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04215-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T04:12:21Z","timestamp":1659413541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04215-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04215-3","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The collection of bronchial and nasal epithelial cells, as well as their study to investigate the mechanisms of transepithelial ion transport and the response to CFTR modulators, were specifically approved by the Ethics Committee of the Istituto Giannina Gaslini following the guidelines of the Italian Ministry of Health (registration numbers: Comitato Regione Liguria ANTECER 042-09\/07\/2018 for bronchial cells and CER: 28\/2020 for nasal cells). Each patient provided informed consent to the study using a form that was also approved by the Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the donors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"192"}}